08:00 | Registration |
|
Cell Line Development |
| |
09:00 |  | Keynote Presentation Quality Control of Cell Lines
John Masters, Professor, University College London, United Kingdom
Quality control is often low on the agenda of cell culture scientists. Perhaps the most important aspect is cell line authentication, the main topic of this lecture. |
|
09:30 | Novel Approaches to Cell Line Development
Mark Smales, Professor, University of Kent, United Kingdom
This presentation will discuss a high-through put screening approach developed to select for CHO cell lines at the multi well plate stage that will generate 2+ g/L of antibody at the bioreactor scale. |
10:00 |  | Keynote Presentation Industry Cell Lines: Challenges and Trends
Jianguo Yang, Principal Scientist and Senior Manager, Genzyme/Sanofi, United States of America
This presentation is an overview for the major challenges, including vector and host engineering, clone selection and cell line stability, cell banking, platform medium and process development, product quality assessment and their future trends. |
|
10:30 | Coffee Break and Networking in the Exhibition Hall |
|
3D Cell Culture |
| |
11:15 | The Famous vs. The Inconvenient – or Why Use 3D-Culture Systems
Eric Gottwald, Principal Investigator, Karlsruher Institute for Technology, Germany
One of the boosts for the development of new 3D-culture techniques is due to elaborated manufacturing and surface modification techniques, especially micro and nano systems technologies that have either improved dramatically or have evolved even lately. |
11:45 | Alvetex: Technology That Enables Routine 3D Cell Culture
Stefan Przyborski, Professor, University of Durham, United Kingdom
Alvetex® scaffold technology provides a solution for generating real three dimensional (3D) cell culture simply and routinely, overcoming the limitations imposed by conventional culture methods. Data will be presented showing how cells growing in alvetex® scaffold demonstrate improved viability, functionality and form complex structures not seen with traditional 2D cell culture. |
12:15 |  Technology Spotlight:
Manufacturing Cell Therapy Products – Current and Future Challenges
Christian Bos, Executive Program Manager, Lonza AG
Cell therapy products are currently manufactured in semi-manual processes. These are suitable to provide product for clinical trials and early commercialization phases. Beyond this, cell therapy products will have to be manufactured and processed in truly scalable systems and Lonza is developing such processes.
|
12:30 | Lunch and Networking in the Exhibition Hall |
13:30 | Poster Session |
14:15 | Development of a 3D Culture System for an in vitro Model of Human Trabecular Meshwork
Susan Sharfstein, Associate Professor, University of Albany, United States of America
This presentation will discuss our efforts to culture human trabecular meshwork cells on novel porous substrates. We envision that these cultures will serve as an in vitro model to test new glaucoma therapies, helping to reduce the incidence of glaucoma-induced blindness. |
14:45 | 3D Organotypic Cultures and Future Perspectives of Such Techniques in Predictive Toxicology Using "omics"
Fozia Noor, Biochemical Engineer, Saarland University, Germany
Different 3D cultivation methods used in our lab will be presented. Such systems allow long term maintenance of liver cells and their use for chronic repeated dose toxicity assessment. |
15:15 | Coffee Break and Networking in the Exhibition Hall |
|
Application and Manipulation of Cultured Cells |
| |
16:00 | Guilt by Association: Coexpression Analysis of the CHO Transcriptome
Colin Clarke, Research Scientist, Dublin City University, Ireland
This talk will focus on the methodology and findings from one of the largest and most diverse analyses of the CHO transcriptome to date. A new online tool to make CHO gene coexpression data publically available in a user-friendly manner will also be discussed. |
16:30 | Proteomic Analysis of Chinese Hamster Ovary Cells; Application to Understanding the Role of miRNAs as Potential Engineering Targets in Bioprocess-Relevant Phenotypes
Paula Meleady, Senior Research Scientist/Programmer, Dublin City University, Ireland
This presentation will review the use of proteomics technology to better understand bioprocess-relevant phenotypes and to investigate the impact of MicroRNAs (miRNAs) on the proteome of recombinant Chinese hamster ovary cell lines. |
17:00 | Public Funding for Academic Bioprocessing Research in the UK
Ben Sykes, Senior Business Interface Manager (Pharmaceuticals/BRIC, BBSRC, United Kingdom
The UK Government recognises the importance of academic research in bioprocessing and often views it in the context of the development of new products or technologies for the pharmaceutical industry. As a result, funding schemes aimed specifically at bioprocessing usually attempt to underpin industrial needs. This presentation will highlight the most relevant funding schemes and also other more general opportunities that academics in this area can pursue. |
17:30 | Drinks Reception |
